PharmacyCodes



Serensiloline en es it fr

Serensiloline Brand names, Serensiloline Analogs

Serensiloline Brand Names Mixture

  • No information avaliable

Serensiloline Chemical_Formula

C2H8O7P2

Serensiloline RX_link

http://www.rxlist.com/cgi/generic2/didronel.htm

Serensiloline fda sheet

Serensiloline FDA

Serensiloline msds (material safety sheet)

Serensiloline MSDS

Serensiloline Synthesis Reference

No information avaliable

Serensiloline Molecular Weight

206.028 g/mol

Serensiloline Melting Point

No information avaliable

Serensiloline H2O Solubility

No information avaliable

Serensiloline State

Solid

Serensiloline LogP

-2.734

Serensiloline Dosage Forms

Solution for injection (50mg/mL); Tablet (200, 400 mg)

Serensiloline Indication

For the treatment of symptomatic Paget's disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury.

Serensiloline Pharmacology

Etidronate is a first generation (non-nitrogenous) bisphosphonate in the same family as clodronate and tiludronate. Etidronate affects calcium metabolism and inhibits bone resorption and soft tissue calcification. Of the etidronate that is resorbed (from oral preparation) or infused (for intravenous drugs), about 50% is excreted unchanged by the kidney. The remainder has a very high affinity for bone tissue, and is rapidly absorbed onto the bone surface. Etidronate has been shown to prevent or delay skeletal-related events and decrease bone pain as well as normalize calcium levels in the presence of hypercalcemia.

Serensiloline Absorption

The amount of drug absorbed after an oral dose is approximately 3%.

Serensiloline side effects and Toxicity

Clinical experience with acute etidronate overdosage is extremely limited. Decreases in serum calcium following substantial overdosage may be expected in some patients. Signs and symptoms of hypocalcemia also may occur in some of these patients. Some patients may develop vomiting. In one event, an 18-year-old female who ingested an estimated single dose of 4800 to 6000 mg (67 to 100 mg/kg) of etidronate was reported to be mildly hypocalcemic (7 .5 2 mg/ dl) and experienced paresthesia of the fingers.

Serensiloline Patient Information

Serensiloline Organisms Affected

Humans and other mammals